Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

  • End date
    Jun 21, 2026
  • participants needed
  • sponsor
    Gustave Roussy, Cancer Campus, Grand Paris
Updated on 21 January 2021


The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-dsoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma

Condition Seminoma
Treatment cisplatin, etoposide, carboplatin
Clinical Study IdentifierNCT01887340
SponsorGustave Roussy, Cancer Campus, Grand Paris
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

Histologically proved seminoma after orchiectomy
Primary testicular or retroperitoneal
Normal alpha-fetoprotein before and after orchiectomy
No prior treatment with radiotherapy or chemotherapy
Age >= 18 years
ECOG 0 to 2
PNN >= 1500, platelets >= 100 000, bilirubin <= the upper limit nromale
ASAT (SGOT) and ALAT (SGPT) <= 1,5 x the upper limit nromale
Serum creatinine <140 mol / L (or clearance> 60 mL / min)
Information and signed informed consent before inclusion in the study
Patient affiliated to a social security
Specific inclusion criteria for cohort 1
grade I
Specific inclusion criteria for cohort 2
grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of the LDH)
grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the LDH)
grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and LDH < 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis and LDH < 2 times normal limit) either at initial diagnosis or relapse of a grade I seminoma)
PET-TDM positive (pathological fixation on metastatic lesions)

Exclusion Criteria

Patient infected by HIV, Hepatitis B or C
History, within 5 years, of cancer other than seminoma, except for treated skin cancer (Basal Cell)
visceral metastasis
cerebral metastasis
Any physical or mental condition incompatible with the treatment (to the investigator discretion)
Uncontrolled or severe cardiovascular pathology
Uncontrolled or severe hepatic pathology
Persons deprived of liberty or under guardianship
Unable to undergo medical monitoring due to geographical, social or psychological reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note